Plasmid DNA vaccines, according to a study, do not elicit a strong enough immune response, necessitating multiple injections or the use of an adjuvant to boost adaptive immunity [21].

As a substitute for engaging nanoparticles for coronavirus vaccine production, whole spike protein or viral components could be encapsulated or self-assembled in nanoparticles.

Advances in nanotechnology have facilitated the rapid development of novel candidate vaccination formulations. Latest nanotechnology policies with desired physical, chemical, and biological qualities, like polymer matrixes and hydrogels, or recently developed nanotechnology platforms with desired physical, chemical, and biological qualities, are promising for targeted antigen delivery and disease transmission prevention [19].

Despite the fact that various peptide vaccines were developed and are used in preclinical testing, only a few Coronavirus peptide vaccines managed to enter clinical trials.

“EpiVac Corona” for example, is a Russian-based vaccine that combines synthetic SARS-CoV-2 peptide antigens with a protein carrier and is adsorbed over an aluminium containing adjuvant [20].

After intramuscular delivery, this vaccine has proved to truly produce/create protective immunity in phase 1 and 2 clinical studies. Another example is “UB-612”, a peptide vaccine that has progressed through phase 2 and 3 clinical trials and was developed by COVAXX and united biomedical [21].

Because vaccination effectiveness has floated as mutations in concern variants have been acquired, Coronavirus might have a similar phenotype to "influenza mismatch," which is produced by substantial and minor changes in circulating viruses. As a result, the virus in the vaccination did not match the circulating strain, reducing its efficacy. The creation of a quadrivalent inactivated vaccine based on the most frequent strains detected in the previous season under continual observation was prompted by the recurring mutations of influenza viruses. While spreading through diverse populations under a range of settings, the viral genome is susceptible to antigenic shift and antigenic drift. This might eventually lead to the emergence of a resistant strain. A mutation force can be formed by putting too much pressure on the S protein as a target antigen. Vaccination, like in the case of influenza, can help to create seasonal immunity. In addition to vaccine development, vaccine distribution across the world is critical to the achievement of strategic herd immunity through vaccination [22].

## CONCLUSION

During a pandemic, monitoring circulating strains is critical for understanding viral strain dynamics and the emergence of new variants.

The goal of this research was to find evolutionary differences in a significant number of severe acute respiratory syndrome coronavirus-2 genomes and speculate on their implications. Positive selection pressure and mutations affecting a specific gene encoding protein (surface glycoprotein) were discovered, which could be utilised to generate vaccines and/or medical medications (nsp12). Negative selection, which has been observed in multiple COVID-19 protein coding genes, could contribute in the development of new diagnostic procedures. Finally, pinpointing specific COVID-19 glycosylation sites may help in understanding the virus's relationship with its receptor and future mutagenesis research, both of which are important for efforts to hinder COVID-19 entrance into cells.

Identifying putative COVID-19 adaptation indicators, on the other hand, is crucial for guiding the production of vaccines and treatment approaches. Thus, Coronavirus mutations must be thoroughly investigated, especially for developing treatments, vaccines, and phenotypic diagnostics.

## REFERENCES

1. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579:270-273.
2. Shaw LP, Wang AD, Dylus D, et al. The phylogenetic range of bacterial and viral pathogens of vertebrates. Mol Ecol 2020; 29:3361-3379.
3. Dawood AA. Mutated COVID-19 may foretell a great risk for mankind in the future. New Microbes New Infect 2020; 35:100673.
4. Tang JW, Tambyah PA, Hui DS. Emergence of a new SARS-CoV-2 variant in the UK. J Infect 2021; 82:27-28.
5. Tang JW, Toovey OTR, Harvey KN, Hui DDS. Introduction of the South African SARS-CoV-2 variant 501Y.V2 into the UK. J Infect 2021; 82:8-10.
6. Tan KK, Tan JY, Wong JE, et al. Emergence of B. 1.524(G) SARS-CoV-2 in Malaysia during the third COVID-19 epidemic wave. Sci Rep 2021; 11:22105.
7. Van Dorp L, Acman M, Richard D, et al. Emergence of genomic diversity and recurrent mutations in SARS-CoV-2. Infect Genet Evol. 2020; 83:104351.
8. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol 2015; 1282:1–23.
9. Snijder EJ, Bredenbeek PJ, Dobbe JC, et al. Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineages. J Mol Biol 2003; 331:991–1004.
10. Minskaia E, Hertzig T, Gorbalenya AE, et al. Discovery of an RNA virus 3 ’-> 5 ’ exoribonuclease that is critically involved in coronavirus RNA synthesis. Proc Natl Acad Sci U SA. 2006; 103:5108–5113.

11. Lo Presti A, Rezza G, Stefanelli P. Selective pressure on SARS-CoV-2 protein coding genes and glycosylation site prediction. Heliyon 2020; 6:05001.
12. Ostrov, David A, and Glenn W Knox. "Emerging mutation patterns in SARS-CoV-2 variants." Biochem Biophys Res Commun 2021; 586:87-92.
13. Li Dan, Jing ding, Ti li liu, et al. "SARS-CoV-2 receptor binding domain radio-probe: a non-invasive approach for angiotensin-converting enzyme 2 mapping in mice."Acta pharmacol Sin 2021; 1–9.
14. Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2-human protein-protein interaction map reveals drug targets and potential drug-repurposing. Nature 2020; 002386.
15. Chauhan G, Madou MJ, Kalra S, et al. Nanotechnology for COVID-19: Therapeutics and Vaccine Research. ACS Nano 2020; 14:7760-7782.
16. Mengist HM, Kombe Kombe AJ, Mekonnen D, et al. Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. Semin Immunol 2021; 55: 101533.
17. Mulu A, Gajaa M, Woldekidan HB, et al. The impact of curcumin derived polyphenols on the structure and flexibility COVID-19 main protease binding pocket: a molecular dynamics simulation study. PeerJ 2021; 9:11590.
18. Hobernik, Dominika, and Matthias Bros. "DNA Vaccines-How Far From Clinical Use." Int J Mol Sci 2018; 19:3605.
19. Lurie N, Saville M, Hatchett R, et al. Developing COVID-19 Vaccines at Pandemic Speed. N Engl J Med 2020; 382:1969-1973.
20. Precision Vaccinations. EpiVacCorona Vaccine.
21. Guirakhoo F, Kuo L, Peng J, et al. A Novel SARS-CoV-2 Multitope Protein/Peptide Vaccine Candidate is Highly Immunogenic and Prevents Lung Infection in an Adeno Associated Virus Human Angiotensin-Converting Enzyme 2 (AAV hACE2) Mouse Model and non-human primates. bioRxiv 2021.
22. Kandimalla Ramesh, Chakraborty P, Vallamkondu J et al. "Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges." Biomedicines 2021; 9:1740.